Advertisement

Re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
  • Lingti Kong
    Correspondence
    Corresponding author: Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
    Affiliations
    Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China

    School of Pharmacy, Bengbu Medical College, Bengbu, China
    Search for articles by this author
  • Li Rong
    Affiliations
    Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China

    School of Pharmacy, Bengbu Medical College, Bengbu, China
    Search for articles by this author
  • Muhua Wang
    Affiliations
    Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China

    School of Pharmacy, Bengbu Medical College, Bengbu, China
    Search for articles by this author
      We read a very interesting article by Hulshof EC et al. in which they studied the role of UGT1A1 genotype guidance in irinotecan administration [
      • Hulshof E.C.
      • de With M.
      • de Man F.M.
      • Creemers G.J.
      • Deiman B.
      • Swen J.J.
      • et al.
      UGT1A1 genotype-guided dosing of irinotecan: a prospective safety and cost analysis in poor metaboliser patients.
      ]. Although the association of UGT1A1 polymorphisms with irinotecan-related toxicity is well established [
      • Hulshof E.
      • Deenen M.
      • Guchelaar H.
      • Gelderblom H.
      Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: ready for prime time.
      ,
      • Mhandire D.Z.
      • Goey A.K.L.
      The value of pharmacogenetics to reduce drug-related toxicity in cancer patients.
      ,
      • Karas S.
      • Innocenti F.
      All you need to know about UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide.
      ], there is insufficient evidence for the effect of genotype-guided dose adjustment on clinical outcomes, so genetic testing is not yet routinely performed before starting irinotecan therapy currently [
      • Hulshof E.
      • Deenen M.
      • Guchelaar H.
      • Gelderblom H.
      Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: ready for prime time.
      ,
      • Mhandire D.Z.
      • Goey A.K.L.
      The value of pharmacogenetics to reduce drug-related toxicity in cancer patients.
      ,
      • Karas S.
      • Innocenti F.
      All you need to know about UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hulshof E.C.
        • de With M.
        • de Man F.M.
        • Creemers G.J.
        • Deiman B.
        • Swen J.J.
        • et al.
        UGT1A1 genotype-guided dosing of irinotecan: a prospective safety and cost analysis in poor metaboliser patients.
        Eur J Cancer. 2022; 162: 148-157https://doi.org/10.1016/j.ejca.2021.12.009
        • Hulshof E.
        • Deenen M.
        • Guchelaar H.
        • Gelderblom H.
        Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: ready for prime time.
        Eur J Cancer. 2020; 141: 9-20https://doi.org/10.1016/j.ejca.2020.09. 007
        • Mhandire D.Z.
        • Goey A.K.L.
        The value of pharmacogenetics to reduce drug-related toxicity in cancer patients.
        Mol Diagn Ther. 2022; https://doi.org/10.1007/s40291-021-00575-x
        • Karas S.
        • Innocenti F.
        All you need to know about UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide.
        JCO Oncol Pract. 2021; (OP2100624)https://doi.org/10.1200/op.21.00624
        • Campbell J.
        • Stephenson M.
        • Bateman E.
        • Peters M.
        • Keefe D.
        • Bowen J.
        Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
        Pharmacogenomics J. 2017; 17: 21-28https://doi.org/10.1038/tpj.2016.58
        • Zhang X.
        • Duan R.
        • Wang Y.
        • Liu X.
        • Zhang W.
        • Zhu X.
        • et al.
        FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial.
        Ther Adv Med Oncol. 2022; 14 (17588359211068737)https://doi.org/10.1177/17588359211068737
        • Iwasa S.
        • Muro K.
        • Morita S.
        • Park Y.
        • Nakamura M.
        • Kotaka M.
        • et al.
        Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
        Cancer Sci. 2021; 112: 4669-4678https://doi.org/10.1111/cas.15092
        • de Man F.
        • Goey A.
        • van Schaik R.
        • Mathijssen R.
        • Bins S.
        Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics.
        Clin Pharmacokinet. 2018; 57: 1229-1254https://doi.org/10.1007/s40262-018-0644-7

      Linked Article